Ikena Oncology, INC

ImageneBio, Inc. announced the appointment of Yanina Grant-Huerta as Chief Financial Officer and the transition of Chief Medical Officer Benjamin Porter-Brown to a consulting role.

ImageneBio, Inc. announced the resignation of Robert Lally, Senior Vice President of Finance and Operations, effective July 22, 2026.

ImageneBio, Inc. announced the approval of an amendment to its 2025 Equity Incentive Plan, increasing authorized shares and including convertible securities in reserve calculations.

ImageneBio, Inc. announced a $30 million private placement of pre-funded warrants to institutional and accredited investors to fund late-phase development and expand indications for its product candidates.

ImageneBio, Inc. announced the mutual separation of its Principal Accounting Officer, Erin Butler, and the appointment of Bob Lally to the role, effective March 20, 2026.

IMAGENEBIO, INC. announced the resignation of its Chief Medical Officer, Dr. Yufang Lu, effective December 31, 2025, with a search for a replacement initiated.

ImageneBio, Inc. reports significant cash increase post-merger and PIPE financing, while advancing its lead asset IMG-007 for atopic dermatitis despite ongoing losses and an identified material weakness in internal controls.

Ikena Oncology, Inc. reported continued net losses in Q2 2025 as it winds down its internal clinical programs and progresses towards a strategic merger with Inmagene Biopharmaceuticals, approved by stockholders.

Ikena Oncology's Q1 2025 results reflect reduced operating expenses amid a strategic merger with Inmagene Biopharmaceuticals, with the merger and related financing expected to close in mid-2025.

Ikena Oncology's Q3 2024 report highlights a strategic shift towards clinical-stage programs, particularly IK-595, alongside a significant workforce reduction and ongoing exploration of strategic options.

Ikena Oncology announced its second quarter 2024 results, highlighting a strategic shift towards its IK-595 program and a reduction in workforce, while also exploring strategic options for the company.

Ikena Oncology's first quarter 2024 results show a net loss of $16.1 million, with a strategic shift towards clinical-stage programs and a workforce reduction.

Ikena Oncology is set to merge with Inmagene Biopharmaceuticals, pivoting its focus to immunology and inflammatory diseases while legacy oncology programs may yield future value for Ikena investors.

Ikena Oncology's 10-K filing highlights its focus on targeted oncology therapies, particularly IK-930 and IK-595, and its progress in clinical trials.

Kristin Yarema, Chief Executive Officer and a Director of Ikena Oncology, Inc., reported multiple transactions in common stock on July 25, 2026.

Robert B Lally, Principal Accounting Officer of Ikena Oncology, Inc., sold 3,196 shares of common stock on July 16, 2026.

Jonathan Jian Wang, a Director at ImageneBio, Inc., acquired stock options for 15,600 shares.

ImageneBio, Inc. director Otello Stampacchia acquired stock options for 15,600 shares.

ImageneBio, Inc. reports that Director Joseph P. Slattery acquired stock options for 15,600 shares.

ImageneBio, Inc. Director David P. Bonita acquired 15,600 stock options with an exercise price of $5.45, vesting under specific conditions.

Ikena Oncology's upcoming annual meeting on June 7, 2024, will address the election of directors and ratification of the company's accounting firm.

Ikena Oncology will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to elect directors and ratify the appointment of its independent accounting firm.

ImageneBio, Inc., formed from the merger of Ikena Oncology and Inmagene Biopharmaceuticals, filed an S-1 registration statement for the resale of 2,508,337 common shares by selling stockholders following a $75 million PIPE financing.

OrbiMed Advisors and affiliated entities increased their beneficial ownership in ImageneBio, Inc. following participation in a 2026 private placement of pre-funded warrants.

Omega Fund VI, L.P. and associated entities have reported beneficial ownership of 8.4% of ImageneBio, Inc. common stock following recent financing.

OrbiMed Advisors and its affiliates have updated their beneficial ownership in ImageneBio, Inc. to 6.92% after a 1-for-12 reverse stock split and a Private Investment in Public Equity (PIPE) transaction, which included a significant share purchase by an OrbiMed entity at a notably lower price than other PIPE investors.

Atlas Venture funds report a significant dilution of their beneficial ownership in ImageneBio, Inc. to 3.6% following the company's merger with Inmagene Biopharmaceuticals and a 1-for-12 reverse stock split.

BML Investment Partners and Braden M. Leonard have significantly reduced their beneficial ownership in Ikena Oncology, Inc., ceasing to be a 5% holder after recent share sales.

OrbiMed Advisors and its affiliated entities have increased their beneficial ownership limitation in Ikena Oncology, Inc. to 19.99%, leading to the conversion of over 6 million non-voting shares into common stock.

Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, reporting beneficial ownership of 959,337 shares of ImageneBio, Inc. common stock, representing 8.51% of the class.

Trails Edge Capital Partners and affiliates have reported a 9.9% beneficial ownership stake in ImageneBio, Inc. through common stock and pre-funded warrants.

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in IMAGENEBIO, Inc. common stock.

Blue Owl Capital Holdings LP has reported a 7.37% beneficial ownership stake in ImageneBio, Inc., holding 823,785 shares of common stock.

Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, reported a passive beneficial ownership of 5.8% in ImageneBio, Inc. common stock.

Biotechnology Value Fund L.P. and its affiliates reported a 7.2% beneficial ownership stake in ImageneBio, Inc. common stock as of September 30, 2025.